

Declaration of Interests Register

Committee C

Publication Date: 12/08/2020

Topic: ID1586 Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma

Name	Role with NICE	Type of interest	Description of interest	Relevant dates			Comments
				Interest arose	Interest declared	Interest ceased	
Prithwiraj Das	Committee Member	non-financial and personal interest	Prithwiraj works at Boehringer Ingelheim Ltd as Market Access Lead in Specialty Medicines (Oncology, Inflammation, Lytics).		02/06/2020		It was agreed that this declaration would not prevent Prithwiraj from participating on this topic.
Ruth Pettengell	Clinical Expert	Indirect	she worked on an advisory board for Takeda.		02/06/2020		It was agreed that this declaration would not prevent Ruth from participating on this topic
Kate Cwynarski	Clinical Expert	direct financial	She worked in a consulting/advisory role for Takeda and attended conferences and received travel support from Roche.		02/06/2020		It was agreed that this declaration would not prevent Kate from participating on this topic.

Christopher Fox	Clinical Expert	direct financial	He was a remunerated expert clinical advisor for and received travel/accommodation support from Takeda he also provided research support to Department of Clinical Haematology, Nottingham University Hospitals NHS Trust		02/06/2020		It was agreed that this declaration would not prevent Christopher from participating on this topic.
Steven Scowcroft	Patient Expert	indirect	Lymphoma Action are supported by pharma organisations including the one involved with this HTA		02/06/2020		It was agreed that this declaration would not prevent Steven from participating on this topic.